Selected research
Industry Research
Follicular Lymphoma Drugs Industry Research Report 2026
Market perspective
The global Follicular Lymphoma Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Follicular Lymphoma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Follicular Lymphoma Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Follicular Lymphoma Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Follicular Lymphoma Drugs include Eisai, Teva, Novartis, Roche, Pfizer, FOSUNKite, Bayer, Beigene and Secura Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Follicular Lymphoma Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Follicular Lymphoma Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Follicular Lymphoma Drugs Market by Company
Eisai
Teva
Novartis
Roche
Pfizer
FOSUNKite
Bayer
Beigene
Secura Bio
MundiPharma
JW Therapeutics
Gilead Sciences
Epizyme
Eagle Pharmaceuticals
Bristol-Myers Squibb
Acrotech Biopharma
Follicular Lymphoma Drugs Segment by Type
Anti-CD20 mAbs
Kinase Inhibitor
Chemotherapy Agents
Others
Follicular Lymphoma Drugs Segment by Application
Injection
Oral
Follicular Lymphoma Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Follicular Lymphoma Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-CD20 mAbs
- Kinase Inhibitor
- Chemotherapy Agents
- Others
Applications
- Injection
- Oral
Companies covered
- Eisai
- Teva
- Novartis
- Roche
- Pfizer
- FOSUNKite
- Bayer
- Beigene
- Secura Bio
- MundiPharma
- JW Therapeutics
- Gilead Sciences
- Epizyme
- Eagle Pharmaceuticals
- Bristol-Myers Squibb
- Acrotech Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Follicular Lymphoma Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Anti-CD20 mAbs
- 2.2.3 Kinase Inhibitor
- 2.2.4 Chemotherapy Agents
- 2.2.5 Others
- 2.3 Follicular Lymphoma Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Injection
- 2.3.3 Oral
- 2.4 Assumptions and Limitations
3 Follicular Lymphoma Drugs Breakdown Data by Type
- 3.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2027-2032)
4 Follicular Lymphoma Drugs Breakdown Data by Application
- 4.1 Global Follicular Lymphoma Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Follicular Lymphoma Drugs Market Perspective (2021-2032)
- 5.2 Global Follicular Lymphoma Drugs Growth Trends by Region
- 5.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Follicular Lymphoma Drugs Market Dynamics
- 5.3.1 Follicular Lymphoma Drugs Industry Trends
- 5.3.2 Follicular Lymphoma Drugs Market Drivers
- 5.3.3 Follicular Lymphoma Drugs Market Challenges
- 5.3.4 Follicular Lymphoma Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Follicular Lymphoma Drugs Players by Revenue
- 6.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Follicular Lymphoma Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Follicular Lymphoma Drugs Head Office and Area Served
- 6.4 Global Follicular Lymphoma Drugs Players, Product Type & Application
- 6.5 Global Follicular Lymphoma Drugs Manufacturers Established Date
- 6.6 Global Follicular Lymphoma Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Follicular Lymphoma Drugs Market Size (2021-2032)
- 7.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 7.4 North America Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Follicular Lymphoma Drugs Market Size (2021-2032)
- 8.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 8.4 Europe Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Follicular Lymphoma Drugs Market Size (2021-2032)
- 10.2 South America Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 10.4 South America Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eisai
- 12.1.1 Eisai Company Information
- 12.1.2 Eisai Business Overview
- 12.1.3 Eisai Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.1.4 Eisai Follicular Lymphoma Drugs Product Portfolio
- 12.1.5 Eisai Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.2.4 Teva Follicular Lymphoma Drugs Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.3.4 Novartis Follicular Lymphoma Drugs Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.4.4 Roche Follicular Lymphoma Drugs Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.5.4 Pfizer Follicular Lymphoma Drugs Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 FOSUNKite
- 12.6.1 FOSUNKite Company Information
- 12.6.2 FOSUNKite Business Overview
- 12.6.3 FOSUNKite Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.6.4 FOSUNKite Follicular Lymphoma Drugs Product Portfolio
- 12.6.5 FOSUNKite Recent Developments
- 12.7 Bayer
- 12.7.1 Bayer Company Information
- 12.7.2 Bayer Business Overview
- 12.7.3 Bayer Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.7.4 Bayer Follicular Lymphoma Drugs Product Portfolio
- 12.7.5 Bayer Recent Developments
- 12.8 Beigene
- 12.8.1 Beigene Company Information
- 12.8.2 Beigene Business Overview
- 12.8.3 Beigene Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.8.4 Beigene Follicular Lymphoma Drugs Product Portfolio
- 12.8.5 Beigene Recent Developments
- 12.9 Secura Bio
- 12.9.1 Secura Bio Company Information
- 12.9.2 Secura Bio Business Overview
- 12.9.3 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.9.4 Secura Bio Follicular Lymphoma Drugs Product Portfolio
- 12.9.5 Secura Bio Recent Developments
- 12.10 MundiPharma
- 12.10.1 MundiPharma Company Information
- 12.10.2 MundiPharma Business Overview
- 12.10.3 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.10.4 MundiPharma Follicular Lymphoma Drugs Product Portfolio
- 12.10.5 MundiPharma Recent Developments
- 12.11 JW Therapeutics
- 12.11.1 JW Therapeutics Company Information
- 12.11.2 JW Therapeutics Business Overview
- 12.11.3 JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.11.4 JW Therapeutics Follicular Lymphoma Drugs Product Portfolio
- 12.11.5 JW Therapeutics Recent Developments
- 12.12 Gilead Sciences
- 12.12.1 Gilead Sciences Company Information
- 12.12.2 Gilead Sciences Business Overview
- 12.12.3 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.12.4 Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
- 12.12.5 Gilead Sciences Recent Developments
- 12.13 Epizyme
- 12.13.1 Epizyme Company Information
- 12.13.2 Epizyme Business Overview
- 12.13.3 Epizyme Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.13.4 Epizyme Follicular Lymphoma Drugs Product Portfolio
- 12.13.5 Epizyme Recent Developments
- 12.14 Eagle Pharmaceuticals
- 12.14.1 Eagle Pharmaceuticals Company Information
- 12.14.2 Eagle Pharmaceuticals Business Overview
- 12.14.3 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.14.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
- 12.14.5 Eagle Pharmaceuticals Recent Developments
- 12.15 Bristol-Myers Squibb
- 12.15.1 Bristol-Myers Squibb Company Information
- 12.15.2 Bristol-Myers Squibb Business Overview
- 12.15.3 Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.15.4 Bristol-Myers Squibb Follicular Lymphoma Drugs Product Portfolio
- 12.15.5 Bristol-Myers Squibb Recent Developments
- 12.16 Acrotech Biopharma
- 12.16.1 Acrotech Biopharma Company Information
- 12.16.2 Acrotech Biopharma Business Overview
- 12.16.3 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2021-2026)
- 12.16.4 Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
- 12.16.5 Acrotech Biopharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst